ofthegreenes Wednesday, 10/25/17 10:55:10 AM Re: ByMorStock post# 288 Post # of 340 https://sheridandaily.com/the-street-expecting-0-23-per-share-for-sangamo-therapeutics-inc-nasdaqsgmo/347791/ Zacks provides a simplified scale for analyst recommendations. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) currently has an ABR of 1.67 heading into today’s announcement. This ABR has an industry rank of 173. This number is also based on the 6 sell-side firms polled by Zacks. Analysts on a consensus basis are expecting that the stock will reach $16.75 within the year.